Follow-up of patients with well-differentiated thyroid cancer

Thyroid Cancer (Second Edition)

Volumn , Issue , 2005, Pages 199-219

  Shapiro, B ^a   Freitas, J ^b   Gross, M ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84891464767     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/3-540-27845-1_12     Document Type: Chapter

References (69)

1. Mazzaferri E (1995) Impact of initial tumor features and treatment selected on the long term course of differentiated thyroid cancer. Thyroid Today 28:1-13
2. Ron E, Lubin JH, Shore RE et al (1995) Thyroid cancer after exposure to external radiation: a pooled analysis of seven studies. Radiat Res 141:259-277
3. Tuttle RM, Becker DV (2000) The chernobyl accident and its consequences: update at the Millenium. Semin Nucl Med 30:133-140
4. Samaan NA, Maheshwari YK, Nader S et al (1983) Impact of therapy for differentiated carcinoma of the thyroid: an analysis of 706 cases. J Endocrinol Metab 56:1131-1138
5. Clarke SEM (1998) Radioiodine therapy of the thyroid. In: Murray IPC, Ell PJ (eds) Nuclear medicine in clinical diagnosis and therapy. Churchill and Livingstone, Edinburgh, pp 1049-1062
6. Mazzafferi EL, Kloos RT (2001) Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 86:1447-1463
7. Hay ID (1989) Prognostic factors in thyroid carcinoma. Thyroid Today 12:1-9
8. Nygaards BJ, Hegedus L, Gervil M, Hjalgrim H, Soe-Jensen P, Hansen JM (1993) Radioio-dine treatment of multinodular goiter. Br Med J 307:828-832
9. Mazzaferri E (1991) Treating differentiated thyroid carcinoma: where do we draw the line? Mayo Clin Proc 66:105-111
10. DeGroot LJ, Kaplan EL, McCormick M, Straus FH (1990) Natural history, treatment and course of papillary thyroid carcinoma. J Clin Endocrinol Metab 71:414-424
11. Maxon HR, Smith HS (1990) Radioiodine-131 in the diagnosis and treatment of well differentiated thyroid cancer. Endocrinol Metab Clin North Am 19:685-718
12. Riccabona G (1998) Differentiated thyroid carcinoma. In: Murray IPC, Ell PJ (eds) Nuclear medicine in clinical diagnosis and therapy. Churchill and Livingstone, Edinburgh, pp 941-957
13. Goldman JM, Line BR, Aamodt RL et al (1980) Influence of triiodothyronine withdrawal time on 131-I uptake postthyroidectomy for thyroid cancer. J Endocrinol Metab 50:734-739
14. Clark OH, Duh QY (1990) Thyroid cancer. In: Green MA (ed) The thyroid gland. Raven, New York, pp 537-572
15. Sweeney D, Johnston G (2000) Radioiodine treatment of thyroid cancer-II. Maximizing therapeutic and diagnostic 131I uptake. In: Wartofsky L (ed) Thyroid cancer. a comprehensive guide to clinical management. Humana Press, Totowa, NJ, pp 239-250
16. Ladenson PW (2000) Recombinant thyrotropin versus thyroid hormone withdrawal in evaluating patients with thyroid carcinoma. Semin Nucl Med 30:98-106
17. Haugen BR, Pacini F, Reiners C et al (1999) A comparison of recombinant human thyro-tropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 84:3877-3885
18. Harness JK, Fund L, Thompson NW, Burney RE, McLeod MK (1986) Total thyroidectomy: complications and technique. World J Surg 10:781-786
19. Clark OH, Elmhed J (1995) Thyroid surgery-past, present and future. Thyroid Today 38:1-9
20. Lennquist S (1986) Surgical strategy in thyroid carcinoma; a clinical review. Acta Chir Scand 152:321-338
21. Massin JP, Savoie JC, Garnier H, Guiaraudon G, Leger FA, Bacourt P (1984) Pulmonary metastases in differentiated thyroid cacinoma, . Study of 58 cases with implications for the primary tumor treatment. Cancer 53:982-992
22. Freitas JE, Gross MD, Ripley SD, Shapiro B (1986) Radionuclide diagnosis and therapy of thyroid cancer: current status report. In: Freeman LM (ed) Freeman and JohnsonÆs clinical radionuclide imaging. Grune and Stratton, Orlando, FL, pp 1994-2027
23. Shapiro B, Ruffini V, Jarwan A et al (2000) Artifacts, anatomical and physiological variants, and unrelated diseases that might cause false-positive whole body scans in patients with thyroid cancer. Semin Nucl Med 30:115-132
24. Jeevanram RK, Shah DH, Sharma SM, Ganatra RD (1986) Influence of initial large dose on subsequent uptake of therapeutic radioiodine in thyroid cancer patients. Nucl Med Biol 13:277-279
25. Park H (1992) Stunned thyroid after high-dose I-131 imaging. Clin Nucl Med 17:501-502
26. Dadparvars S, Chevres A, Tulchinsky M, Krishna-Badrinath L, Khan AS, Slizofski WJ (1995) Clinical utility of technetium-99m methoxyisobutylisonitrite imaging in Differentiated thyroid carcinoma: comparison with thallium-201 and iodine-131 Na Scintigraphy and thyroglobulin quantitation. Eur J Nucl Med 22:1330-1338
27. Kosuda S, Yokoyama H, Katayama M, Yokokawa T, Kusano S, Yamamoto O (1995) Tech-netium-99m tetrofosmin and technetium-99m sestamibi imaging of multiple metastases from differentiated thyroid carcinoma. Eur J Nucl Med 22:1218-1220
28. Brendel AJ, Guyot M, Jeandot R, Lefolt G, Manicet G (1998) Thallium-201 imaging in the Follow-up of differentiated thyroid carcinoma. J Nucl Med 29:1515-1520
29. Szakall S, Esik O, Bajzik G, Repa I, Dabasi G, Sinkovacs I, Agoston P, Tron L (2002) 18F-FDG PET detection of lymph node metastases in medullary thyroid carcinoma. J Nucl Med 43:66-71
30. Chin B, Patel P, Cohade C, Ewertz M, Wahl R, Ladenson P (2004) Recombinant human-thyrotropin stimulation of fluoro-D-glucose positron emission tomography uptake in well-differentiated thyroid carcinoma. J Clin Endocrinol Metab 89:91-95
31. Kang KW, Kim S-K, Kang H-S et al (2003) Prevalence and risk of cancer of focal thy-roidincidentaloma identified by 18F-fluorodeoxyglucose positron emission tomography for metastasis evaluation and cancer screening in healthy subjects. J Clin Endocrinol Metab 88:4100-4104
32. Baudin E, Schlumberger M, Lumbrosa J et al (1996) Octreotide scintigraphy in patients with Differentiated thyroid carcinoma: contribution for patients with negative radioio-dine scans. J Clin Endocrinol Metab 81:2451-2544
33. Burch HB (2000) Papillary thyroid cancer. Follow up. In: Wartofsky L (ed) Thyroid cancer. a comprehensiveguide to clinical management. Humana Press, Totowa, NJ, pp 229-237
34. Fatourechi V, Hay ID (2000) Treating the patient with differentiated thyroid cancer with thyroglobulin-positive iodine-131diagnostic scan-negative metastases: including comments on the role of serum thyroglobulin monitoring in tumor surveillance. Semin Nucl Med 30:107-114
35. Cailleux AF, Baudin E, Travagli JP, Ricard M, Schlumberger M (2000) Is diagnostic io-dine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer? J Clin Endocrinol Metab 85:175-178
36. Van de Velde CJH, Hamming JF, Goslings BM, Schelfhout LJDM, Clark OH, Smets S et al (1988) Report of the consensus development conference on the management of differentiated thyroid cancer in the Netherlands. Eur J Cancer Clin Oncol 24:287-292
37. Beierwaltes WH, Rabbini R, Dmuchowski C, Lloyd RV, Eyre P, Mallette S (1984) An analy-131 sis of ablation of thyroid remnants with I in 511 patients from 1947-1984. J Nucl Med 25:1287-1293
38. Johnston G, Sweeney D (2000) Radioiodine therapy of thyroid cancer. General considerations. I. In: Wartofsky L (ed) Thyroid cancer. A comprehensive guide to clinical management. Humana Press, Totowa, NJ, pp 147-153
39. Grigsby PW, Baglan K, Siegel BA (1999) Surveillance of patients to detect recurrent thyroid carcinoma. Cancer 85:945-951
40. Burman KD (1995) How serious are the risks of thyroid hormone over-replacement? Thyroid Today 18:1-9
41. Burmeister LA, Goumaz MO, Mariassh CN, Oppenheimer JH (1992) Levothyroxine dose requirements for thyrotropin suppression in the treatment of differentiated thyroid cancer. J Clin Endocrinol Metab 75:344-350
42. Ozata M, Suzuki S, Miyamoto T, Liu RT, Fierro-Renoy F, DeGroot LJ (1994) Serum thy-rotropin in the follow-up of patients with treated differentiated thyroid cancer. J Clin Endocrinol Metab 79:98-105
43. Samaan NA, Schultz PN. Hickey RC, Haynie TP, Johnston DA, Ordonez NG (1992) Well-differentiated thyroid carcinoma and the results of various modalities of treatment. A retrospective review of 1, 599 patients. J Clin Endocrinol Metab 75:714-720
44. Benua RS, Cicale NR, Sonenberg M (1962) The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. AJR 87:171-182
45. Hurley RJ, Becker DV (1983) The use of radioiodine in the management of thyroid cancer. In: Freeman LM, Weissman HS (eds) Nuclear medicine annual. Raven, New York, pp 348-349
46. Wartofsky L (2000) An approach ot the management of patients with scan negative, thyro-globulin positive, differentiated thyroid carcinoma. In: Wartofsky L (ed) Thyroid cancer. A comprehensive guide to clinical management. Humana Press, Totowa, NJ, pp 251-261
47. Deihl M, Risse JH, Brandt-Mainz K, Dietlein M, Bohuslavizki KH, Matheja P, Lange H, Bredow J, Korber C, Grunwald F (2001) Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: results of a multicenter study. Eur J Nucl Med 28:1671-1676
48. Lowe V, Mullan BP, Hay ID, McIver B, Kasperbauer JL (2003) 18F-FDG PET of patients with Hurthle cell carcinoma. J Nucl Med 44:1402-1406
49. Tallroth E, Lundell G, Tennvall J, Wallin G (1990) Chemotherapy and multimodality treatment in thyroid carcinoma: disorders of the thyroid and parathyroid. II. Otolaryn-gol Clin North Am 32:523-527
50. White RL (2000) Management of papillary thyroid carcinoma. In: Wartofsky L (ed) Thyroid cancer. A comprehensive guide to clinical management. Humana Press, Totowa, NJ, pp 225-228
51. Eng C, Clayton D, Schuffenecker I et al (1996) The relationship between specific RET protooncogene mutations and diseased phenotype in multiple endocrine neoplasia type 2: international RET mutation consortium analysis. JAMA 276:1575-1579
52. Ball DW (2000) Medullary thyroid carcinoma. In: Wartofsky L (ed) Thyroid cancer. A comprehensive guide to clinical management. Humana Press, Totowa, NJ, pp 365-381
53. Sisson JC (1989) Medical treatment of benign and malignant thyroid tumors. Endocrinol Metab Clin North Am 18:359-387
54. Kwekkeboom DJ, Reubi JC, Lamberts SWJ et al (1993) In vivo somatostatin-receptor imaging in medullary thyroid carcinoma. J Clin Endocrinol Metab 76:1413-1417
55. Clarke SEM, Lazarus CR, Wraight P, Sampson C, Maisey MN (1988) Pentavalent [99m-Tc] DMSA, [131-I] MIBG, and [99m-Tc] MDP: an evaluation of three imaging techniques in patients with medullary carcinoma of the thyroid. J Nucl Med 29:33-38
56. O'Byrne KJ, Hamilton D, Robinson I, Sweeney E, Freyne PG, Cullen MJ (1992) Imaging of medullary carcinoma of the thyroid using 111-In labeled anti-CEA monoclonal antibody fragments. Nucl Med Commun 13:142-148
57. Clarke SEM, Lazarus CR, Edwards S et al (1987) Scintigraphy and treatment of medullary carcinoma of the thyroid with iodine-131 metaiodobenzylguanidine. J Nucl Med 28:1820-1825
58. Virgolini I, Traub T, Novotny C, Leimer M, Fuger B et al (2001) New trends in peptidereceptor radioligands. Q J Nucl Med 45:153-159
59. Hooft L, Hoekstra OS, Deville W, Lips P, Teule GJJ, Boers M, van Tulder MW (2001) Diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography in the follow up of papillary or follicular cancer. J Clin Endocrinol Metab 86:3779-3786
60. Frilling A, Tecklenborg K, Gorges R, Weber F, Clausen M, Broelsch EC (2001) Preop-erative diagnostic value of [18-F] Fluorodeoxyglucose positron emission tomography in patients with radio-iodine negative recurrent well-differentiated thyroid carcinoma. Ann Surg 234:804-811
61. 131I scanning results. J Nucl Med 42:1464-1496
62. 18F]-fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine. Thyroid 11:1169-1175
63. Clark OH, Hoelting T (1994) Management of patients with differentiated thyroid cancer who have positive serum thyroglobulin levels and negative radioiodine scans. Thyroid 4:501-505
64. Pineda JD, Lee T, Ain K, Reynolds JC, Robbins J (1995) Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. J Clin Endo-crinol Metab 80:1488-1492
65. Maxon HR III (1993) The role of I-131 in the treatment of thyroid cancer. Thyroid Today XVI:1-9
66. Schlumberger M, Arcangioli O, Pickarski JD, Tubiana M, Parmentier C (1988) Detection and treatment of lung metastases of differentiated thyroid carcinoma in patients with normal chest X-rays. J Nucl Med 29:1790-1794
67. Beierwaltes WH (1978) The treatment of thyroid carcinoma with radioactive iodine. Semin Nucl Med 8:79-94
68. Schlumberger MJ (1999) Diagnostic follow-up of well-differentiated thyroid carcinoma: historical perspective and current status. J Endocrinol Invest 22:3-7
69. Pacini F, Agate L et al (2001) Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic I-131 whole body scan: comparison of patients treated with high I-131 activities versus untreated patients. J Clin Endocrinol Metab 86:4092-4097